BioSpace News Archive

The purpose of this press release is to provide supplemental disclosure to the Corporation’s management information circular and proxy statement dated November 26, 2018 in respect of the Annual and Special Meeting of the Shareholders of the Corporation to be held at 10:00 am (Toronto time) on January 8, 2019.

Reprieve Cardiovascular™, a pioneering medical device company focused on improving outcomes for patients suffering from acute decompensated heart failure (ADHF), today announced new clinical study results demonstrating improvements in the ability of Reprieve-Guided Diuretic Therapy to optimize fluid management for people with Acute Decompensated Heart Failure (ADHF).

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has initiated POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization), an international, Phase 3 clinical trial of AR101 in peanut-allergic children ages 1–3 years. AR101 is Aimmune’s investigational biologic oral immunotherapy for desensitization of patients with peanut allergy.

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced chief executive officer Keith A. Katkin is scheduled to present a corporate overview at the J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 8:00 a.m. PT in San Francisco.

ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions potentially leading to anaphylaxis, has raised $20 million in Series C financing led by Deerfield Management.

X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEX™) library drug discovery engine to the generation of novel small molecule therapeutics, today announced the signing of a broad strategic drug discovery collaboration with Bristol-Myers Squibb. T

Hologic, Inc. announced that the Company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 8, 2019 at 11:30 a.m. Pacific Time (PT)

DisposeRx Inc. (http://www.disposerx.com) today announced that senior retail healthcare executive, George Riedl, will serve as a strategic advisor for the company as it continues to expand its relationships with health plans, payors, pharmaceutical manufacturers, pharmacy benefit managers and pharmacies nationwide.

ForeverGreen™ Worldwide Corporation (OTCQB: FVRG), a global direct marketing company and provider of health and wellness products, announces that the company has on-going discussions about utilizing CBD in some of its top selling products.

-Co-authored by Blake Stock, Senior Director of Product ORHub-